Effects on quality of life, major adverse CV events & mortality are likely limited or uncertain. November 2025 Pdf of factsheet : Semaglutide binds to, and activates, the GLP-1 (glucagon-like peptide-1) receptor to increase insulin secretion, suppress glucagon secretion, and slow gastric emptying
Ozempic uses Saxenda is approved by the FDA as a chronic weight-management medication and Ozempic is approved as a treatment for type 2 diabetes and to decrease the risk of cardiovascular disease, kidney disease, and kidney failure in adults with type 2 diabetes and chronic kidney disease
Reviewed by FDA against compounding inclusion in December 2024
Random sequences rapidly evolve into de novo promoters
The main risks stem from its unapproved status and potential for improper compounding
A 2023 study published in the New England Journal of Medicine shows that patients who took the highest dose of Retatrutide lost an average of 24.2% of their body weight in just 48 weeks